The National Institutes of Health today awarded about $470 million from the American Rescue Plan Act to New York University Langone Health for a project to study the long-term effects of COVID-19. The RECOVER (Researching COVID to Enhance Recovery) initiative will work with more than 100 researchers to support new and existing studies of COVID-19 survivors to learn why some people have prolonged symptoms or develop new or returning symptoms after SARS-CoV-2 infection, and potential prevention and treatment strategies. The studies will enroll adult, pregnant and pediatric patients during the acute and post-acute phases of infection; evaluate tissue pathology and electronic health records; and use smartphone apps and other mobile technologies to gather data in real time. 

“Given the range of symptoms that have been reported, intensive research using all available tools is necessary to understand what happens to stall recovery from this terrible virus,” said Walter Koroshetz, M.D., director of NIH’s National Institute of Neurological Disorders and Stroke and co-chair of the initiative. “Importantly, the tissue pathology studies in RECOVER will enable in depth studies of the virus’s effects on all body systems.”
 

Related News Articles

Headline
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during…
Headline
The Centers for Disease Control and Prevention last week updated the list of underlying medical conditions that put adults of any age at higher risk for…
Chairperson's File
Working in health care delivery can be stressful and tiring under normal circumstances. And the COVID-19 pandemic has exerted incredible pressures on the…
Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18. The extension…
Headline
The National Institutes of Health yesterday awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2,…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…